The short version of glutathione fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.
Cells synthesize glutathione through two ATP-dependent steps: glutamate-cysteine ligase joins glutamate and cysteine, and glutathione synthetase adds glycine to form the complete tripeptide. Breakdown occurs through gamma-glutamyl transpeptidase and subsequent peptidase reactions, forming the gamma-glutamyl cycle. Within cells, glutathione also forms a disulfide-linked dimer called GSSG when two GSH molecules react. The balance between GSH and GSSG is widely used as an indicator of oxidative conditions, although the ratio can vary by compartment and tissue.
Glutathione supports several cellular processes beyond direct antioxidant action. It serves as a cofactor for glutathione peroxidase and glutathione S-transferase enzymes, which reduce peroxides and conjugate electrophiles, respectively. The molecule also acts as a reservoir of cysteine, an amino acid that can limit protein synthesis and redox signaling. In human nutrition, oral glutathione is sold as a supplement, but how much intact glutathione reaches tissues after ingestion remains an active research question. Clinical claims about supplementation are not uniformly supported by controlled trials.
Glutathione is a small tripeptide built from glutamic acid, cysteine, and glycine. Its peptide bond between glutamate and cysteine involves the gamma-carboxyl group rather than the usual alpha-carboxyl group. This structure gives the molecule a reactive thiol on the cysteine residue. The reduced form, often abbreviated GSH, is the predominant intracellular species in many cell types. Because the thiol can donate electrons, glutathione participates in redox chemistry and in the conjugation of reactive molecules.
Functionally, glutathione supports redox balance by donating electrons and becoming oxidized. It also serves as a cofactor for enzymes such as glutathione peroxidases and glutathione S-transferases. These enzymes participate in peroxide reduction and in conjugation reactions that help process reactive molecules. Separate from antioxidant roles, glutathione can modify protein cysteines through S-glutathionylation, influencing enzyme activity and signaling. Research continues to examine how these chemical roles translate into whole-organism effects.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. Its glutamate-cysteine linkage uses the gamma-carboxyl group of glutamate, a feature that resists standard peptidases. The cysteine residue provides a thiol group, which gives the molecule its reducing character. In cells, glutathione is often the most abundant small-molecule thiol, with concentrations varying widely by tissue and compartment. It exists mainly in a reduced form called GSH, while oxidation produces a disulfide-linked dimer called GSSG.
Biosynthesis proceeds in two ATP-dependent steps. First, glutamate-cysteine ligase joins glutamate and cysteine. Second, glutathione synthetase adds glycine to the intermediate. The pathway is regulated by cysteine availability, enzyme expression, and feedback inhibition by glutathione itself. Liver tissue has a particularly high capacity for synthesis and export. Because the molecule is made inside cells, circulating glutathione reflects a balance of release, uptake, and breakdown rather than simple dietary supply.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C10H17N3O6S | Reduced form; oxidized dimer is C20H32N6O12S2 |
| Molar mass | 307.32 g/mol | For reduced glutathione (GSH) |
| Appearance | White crystalline powder | Typical laboratory and supplement-grade material |
| Solubility | Soluble in water | Poorly soluble in ethanol and other nonpolar solvents |
| Typical storage | -20 C, desiccated, protected from light | Reduced form can oxidize in solution |
Glutathione synthesis proceeds in two ATP-dependent steps catalyzed by glutamate-cysteine ligase and glutathione synthetase. The first step joins glutamate and cysteine to form gamma-glutamylcysteine and is generally rate-limiting. The second step adds glycine to complete the tripeptide. Cysteine availability, feedback inhibition by glutathione, and oxidative conditions influence flux through this pathway. The pathway is conserved across many organisms, and degradation by gamma-glutamyl transpeptidase and related peptidases recycles amino acids for new synthesis.
Within cells, glutathione serves as a cofactor for glutathione peroxidases and glutathione S-transferases. These enzymes reduce hydrogen peroxide and organic peroxides or conjugate electrophilic compounds to the thiol group. The resulting conjugates can be exported and processed through mercapturic acid pathways. Glutathione also contributes to protein thiol homeostasis and to recycling of other antioxidants such as ascorbate. Its precise roles vary by tissue, and many regulatory effects observed in laboratory systems remain difficult to quantify in whole organisms.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. The peptide bond between glutamate and cysteine uses the gamma-carboxyl group of glutamate rather than the alpha-carboxyl group. This unusual linkage protects the molecule from many common peptidases. The cysteine side chain carries a thiol group that can undergo reversible oxidation. Because of this thiol, glutathione participates in redox reactions and helps maintain the reducing environment inside most cells in living systems.
In cells, glutathione exists mainly in a reduced form called GSH. When two GSH molecules react, they form oxidized glutathione, or GSSG, which contains a disulfide bond. The ratio of GSH to GSSG is often used as an indicator of oxidative stress. Enzymes such as glutathione peroxidase and glutathione reductase help cycle the molecule between these two states. This cycling supports antioxidant defense, detoxification of reactive molecules, and regulation of certain signaling pathways.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. Its cysteine residue carries a thiol group, which allows the molecule to participate in reduction and oxidation reactions. The compound exists in most living cells, where the reduced form, often abbreviated GSH, is usually more abundant than the oxidized disulfide form, GSSG. Intracellular concentrations are commonly in the millimolar range, while extracellular concentrations are much lower. This uneven distribution supports its role as a major cellular redox buffer.
Cells synthesize glutathione through two ATP-dependent enzymatic steps. The first step combines glutamate and cysteine to form gamma-glutamylcysteine, catalyzed by glutamate-cysteine ligase. The second step adds glycine, producing the complete tripeptide, catalyzed by glutathione synthetase. Glutathione itself can inhibit the first enzyme, providing negative feedback when levels are high. Because cysteine is often limiting, its availability influences how quickly the pathway proceeds. These reactions occur in the cytosol, and the resulting glutathione can be distributed to other compartments.
Glutathione functions in redox balance, detoxification, and sulfur amino acid storage. It participates in reactions that help maintain ascorbate and protein thiol status. The molecule serves as a cofactor for several enzymes, including glutathione peroxidases and glutathione S-transferases. These enzymes reduce peroxides and conjugate electrophiles, respectively. Glutathione also contributes to the metabolism of xenobiotics and to the transport of cysteine between tissues. How interorgan transport and tissue-specific regulation shape whole-body pools remains an active area of study.
In non-small cell lung cancer, both mRNA and protein levels of TMPRSS11D are elevated in tumor tissue compared with adjacent normal tissue, and high protein expression is an independent predictor of poorer overall survival. Plasminogen (PLG), from which originates the mini-plasmin that can cleave the F-protein, is highly expressed in liver cancers. Its expression is also increased in a wide range of other malignant neoplasms. Factor X (F10) is frequently expressed in normal liver and in liver cancers. SeV constructs were created with a modified protease cleavage site. The modification allowed the recombinant virus to specifically infect cancer cells that expressed the corresponding proteases, which can cleave a modified protease cleavage site.
Collective cell migration describes the movements of group of cells and the emergence of collective behavior from cell-environment interactions and cell-cell communication. Collective cell migration is an essential process in the lives of multicellular organisms, e.g. embryonic development, wound healing and cancer spreading (metastasis). Cells can migrate as a cohesive group (e.g. epithelial cells) or have transient cell-cell adhesion sites (e.g. mesenchymal cells). They can also migrate in different modes like sheets, strands, tubes, and clusters. While single-cell migration has been extensively studied, collective cell migration is a relatively new field with applications in preventing birth defects or dysfunction of embryos. It may improve cancer treatment by enabling doctors to prevent tumors from spreading and forming new tumors.
Brenner's work includes the first human trial of NR, which demonstrated safe oral availability as an NAD+ precursor. His work characterized ways in which the NAD system is disrupted by diseases and conditions of metabolic stress. Further, he identified a specific mechanism by which citrin deficiency results in sweet aversion and metabolic dysfunction-associated steatotic liver disease (MASLD), and identified glycerol-3-phosphate as the activator of carbohydrate response element binding protein (ChREBP).
=== Protein tags === BCCP (Biotin Carboxyl Carrier Protein), a protein domain biotinylated by BirA enabling recognition by streptavidin BromoTag, a "bump-and-hole" mutated version of the second bromodomain of Brd4, Brd4-BD2 L387A, that can be highly selectively bound by tag-specific PROTAC degrader AGB1 to form a ternary complex between the "BromoTagged" protein and the E3 ligase VHL, leading to ubiquitination of the tagged protein and its subsequent rapid and effective proteasomal degradation in cells. FAST (Fluorescence-Activating and absorption-Shifting Tag), a mutated photoactive yellow protein (PYP) that reversibly binds cognate fluorogenic ligands CL7-tag, an engineered variant of Colicin E7 that has a strong binding affinity and specificity for immobilized Immunity Protein 7 (Im7). Glutathione-S-transferase-tag, a protein which binds to immobilized glutathione Green fluorescent protein-tag, a protein which is spontaneously fluorescent and can be bound by nanobodies HaloTag, a mutated bacterial haloalkane dehalogenase that covalently attaches to haloalkane substrates SNAP-tag, a mutated eukaryotic DNA methyltransferase that covalently attaches to benzylguanine derivatives CLIP-tag, a mutated eukaryotic DNA methyltransferase that covalently attaches to benzylcytosine derivatives HUH-tag, a sequence-specific single-stranded DNA binding protein that covalently binds to its target sequence Maltose binding protein-tag, a protein which binds to amylose agarose Nus-tag Thioredoxin-tag Fc-tag, derived from immunoglobulin Fc domain, allow dimerization and solubilization.
Computational chemistry is simplest in gas-phase chemistry, in which interactions between molecules may be ignored as negligible. Multiple authors have researched dubnium pentachloride; calculations show it to be consistent with the periodic laws by exhibiting the properties of a compound of a group 5 element. For example, the molecular orbital levels indicate that dubnium uses three 6d electron levels as expected. Compared to its tantalum analog, dubnium pentachloride is expected to show increased covalent character: a decrease in the effective charge on an atom and an increase in the overlap population (between orbitals of dubnium and chlorine). Calculations of solution chemistry indicate that the maximum oxidation state of dubnium, +5, will be more stable than those of niobium and tantalum and the +3 and +4 states will be less stable. The tendency towards hydrolysis of cations with the highest oxidation state should continue to decrease within group 5 but is still expected to be quite rapid. Complexation of dubnium is expected to follow group 5 trends in its richness. Calculations for hydroxo-chlorido- complexes have shown a reversal in the trends of complex formation and extraction of group 5 elements, with dubnium being more prone to do so than tantalum.
Sources: en.wikipedia.org
== External links == 16S rRNA, BioMineWiki Archived 2019-04-27 at the Wayback Machine Ribosomal Database Project II Archived 2020-08-19 at the Wayback Machine Ribosomal+RNA at the U.S. National Library of Medicine Medical Subject Headings (MeSH) SILVA rRNA Database Project (also includes Eukaryotes (18S) and LSU (23S/28S)) Video: rRNA: sequence, function & synthesis Halococcus morrhuae (archaebacterium) 5S rRNA
== Career == In 1977, Bowman joined International Plasma Corporation of Hayward, California as chief financial officer and general manager of its analytical instrument division. International Plasma Corporation owned Durrum Instrument Corporation, an instrumentation company that had purchased exclusive rights to an emergent technology, Ion chromatography, from Dow Chemical Company. Initial research by Hamish Small and others at the Dow Physical Research Laboratory in Midland, Michigan suggested that inorganic ion analysis would be superior to commonly used wet chemical techniques, but Dow was not interested in pursuing the idea. Bowman became interested in the potential of ion chromatography (IC) while at International Plasma Corporation. In 1980, Smith-Kline acquired International Plasma Corporation. The IC division was spun off as a separate company, under the name Dionex Corporation, in a leveraged buyout (LBO) led by A. Blaine Bowman. Bowman became the president and CEO of the new company, which was incorporated in California in 1980. The company was reincorporated in Delaware in 1986. Dionex began to trade publicly as of 1982. Under Bowman's leadership, Dionex made important advances both scientifically and economically. The company directed up to nine percent of its revenues back into its ongoing research and development program.
Severe adverse effects of EMP are thromboembolic and cardiovascular complications including pulmonary embolism, deep vein thrombosis, stroke, thrombophlebitis, coronary artery disease (ischemic heart disease; e.g., myocardial infarction), thrombophlebitis, and congestive heart failure with fluid retention. EMP produces cardiovascular toxicity similarly to diethylstilbestrol, but to a lesser extent in comparison at low doses (e.g., 280 mg/day oral EMP vs. 1 mg/day oral diethylstilbestrol). The prostate cancer disease state also increases the risk of thromboembolism, and combination with docetaxel may exacerbate the risk of thromboembolism as well. Meta-analyses of clinical trials have found that the overall risk of thromboembolism with EMP is 4 to 7%, relative to 0.4% for chemotherapy regimens without EMP. Thromboembolism is the major toxicity-related cause of discontinuation of EMP. Anticoagulant therapy with medications such as aspirin, warfarin, unfractionated and low-molecular-weight heparin, and vitamin K antagonists can be useful for decreasing the risk of thromboembolism with EMP and other estrogens like diethylstilbestrol and ethinylestradiol. Adverse liver function tests are commonly seen with EMP, but severe liver dysfunction is rare with the medication. Central nervous system side effects are rarely seen with EMP, although enlarged ventricles and neuronal pigmentation have been reported in monkeys treated with very high doses of EMP (20–140 mg/kg/day) for 3 to 6 months. EMP does not appear to have cytostatic effects in normal brain tissue.
The illegal drug trade is the global black market dedicated to the cultivation, manufacture, distribution, and sale of prohibited drugs. The terms drug trafficking and narcotrafficking are also commonly used to describe the trade of the illicit substances. A majority of jurisdictions prohibit trade, except under license, of many types of drugs through the use of drug prohibition laws. The think tank Global Financial Integrity's Transnational Crime and the Developing World report estimates the size of the global illicit drug market between US$426 and US$652 billion in 2014. With a world GDP of US$78 trillion in the same year, the illegal drug trade may be estimated as nearly 1% of total global trade. Consumption of illegal drugs is widespread globally, and it remains very difficult for local authorities to reduce the rates of drug consumption.
Sources: en.wikipedia.org
It is a tripeptide of glutamic acid, cysteine, and glycine. The linkage between glutamate and cysteine uses the gamma-carboxyl group, which is unusual for peptides.
GSH is the reduced form with a free thiol group. GSSG is the oxidized dimer formed when two GSH molecules join by a disulfide bond.
It is synthesized inside cells and is not classified as an essential dietary nutrient for most people. Dietary and supplemental sources are studied, but direct requirements are not established in the same way as for vitamins.
Glutathione is a sulfur-containing tripeptide made from glutamate, cysteine, and glycine. It is found in most cells and participates in redox balance and detoxification reactions.